Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
Authors
Grace G Kim
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
Grace G Kim , Heba Mohamed , Ishmam Bhuiyan , Corin Macphail , Taylor Sidhu , Amir Emami , Longlong Huang , Shaun Zheng Sun , Scott Tyldesley , Jenny J. Ko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 76)
DOI
10.1200/JCO.2024.42.4_suppl.76
Abstract #
76
Poster Bd #
C11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2019 ASCO Annual Meeting
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.
First Author: Catherine Handy Marshall
Poster
2024 ASCO Genitourinary Cancers Symposium
Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.
First Author: Corbin J. Eule